ArticlePloS one2012
Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Serum ferritin as a non-invasive prognostic biomarker in cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Meta-analysis of the prognostic value of pretreatment serum ferritin in hepatobiliary and pancreas (HBP) cancers.BMJ open · 2021Pooled it
- C-reactive protein as a prognostic factor for human osteosarcoma: a meta-analysis and literature review.PloS one · 2014Pooled it
- Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease.Journal of gastrointestinal cancer · 2014Trial
- Chronic inflammatory diseases and survival among breast cancer patients in the U.S. military health system.Breast cancer research and treatment · 2025Article
- The impact of serum ferritin on overall survival following resection in patients with intrahepatic cholangiocarcinoma.Langenbeck's archives of surgery · 2025Article
- Ferritin as an Effective Prognostic Factor and Potential Cancer Biomarker.Current issues in molecular biology · 2025Review
- Serum ferritin level is an effective prognostic factor for lung cancer immunotherapy.Cancer biology & therapy · 2023Article
- Review
- Prognostic Value of International Normalized Ratio-to-Albumin Ratio and Ferritin Level in Chronic Liver Patients with Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2022Article
- The Effect of Serum 25-Hydroxyvitamin D on Serum Ferritin Concentrations: A Longitudinal Study of Participants of a Preventive Health Program.Nutrients · 2019Article
- Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study.BMC complementary and alternative medicine · 2018Article
- Iron in the Tumor Microenvironment-Connecting the Dots.Frontiers in oncology · 2018Review
- Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment.Frontiers in cell and developmental biology · 2018Review
- High preoperative serum ferritin predicted poor prognosis in non-metastatic colorectal cancer.Saudi medical journal · 2017Article
- Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state.Translational research : the journal of laboratory and clinical medicine · 2017Review
- Myoferlin is a novel exosomal protein and functional regulator of cancer-derived exosomes.Oncotarget · 2016Article
- Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer.Journal of Cancer · 2016Article
- miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer.Frontiers in oncology · 2014Article
- The association between the levels of serum ferritin and sex hormones in a large scale of Chinese male population.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately half of all HER2/neu-overexpressing breast cancer patients do not respond to trastuzumab-containing therapy. Therefore, there remains an urgent and unmet clinical need for the development of predictive biomarkers for trastuzumab response. Recently, several lines of evidence have demonstrated that the inflammatory tumor microenvironment is a major contributor to therapy resistance in breast cancer. In order to explore the predictive value of inflammation in breast cancer patients, we measured the inflammatory biomarkers serum ferritin and C-reactive protein (CRP) in 66 patients immediately before undergoing trastuzumab-containing therapy and evaluated their progression-free and overall survival. The elevation in pre-treatment serum ferritin (>250 ng/ml) or CRP (>7.25 mg/l) was a significant predictor of reduced progression-free survival and shorter overall survival. When patients were stratified based on their serum ferritin and CRP levels, patients with elevation in both inflammatory biomarkers had a markedly poorer response to trastuzumab-containing therapy. Therefore, the elevation in inflammatory serum biomarkers may reflect a pathological state that decreases the clinical efficacy of this therapy. Anti-inflammatory drugs and life-style changes to decrease inflammation in cancer patients should be explored as possible strategies to sensitize patients to anti-cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.